Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares ...

One stock that might be an intriguing choice for investors right now is Amylyx Pharmaceuticals, Inc. AMLX. This is because this security in the Medical - Drugs space is seeing solid earnings estimate ...

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) on Wednesday decided to discontinue the ORION program of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO, also known as ursodoxicoltaurine]) in ...

3 small-cap biotechs with potential breakthroughs in 2024 Amylyx Pharmaceuticals (NASDAQ:AMLX) is preparing for a pivotal ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best Middle East and Africa stocks to buy according to hedge ...

Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis (ALS) drug Relyvrio continues to wow Wall Street. Approved in the U.S. as Relyvrio and in Canada under a different brand name, the drug brought in ...

Shares in Amylyx Pharmaceuticals (NASDAQ: AMLX) were up almost 28% in the week to Friday morning. The move comes after an analyst at Guggenheim initiated coverage of the small-cap stock and issued a ...

Amylyx Pharmaceuticals is withdrawing its FDA-approved therapy for amyotrophic lateral sclerosis, Relyvrio, from the market after a phase 3 study failure, the company said April 4. In early March, the ...

Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) acquired avexitide from Eiger BioPharmaceuticals Inc (OTC:EIGRQ) for $35.1 million. Avexitide is an investigational, first-in-class glucagon-like peptide-1 ...

Amylyx Pharmaceuticals is withdrawing its drug for amyotrophic lateral sclerosis from the market, a decision that comes a month after post-marketing clinical trial results showed the medication was no ...

(Reuters) - Amylyx Pharmaceuticals has agreed to buy the rights to bankrupt drugmaker Eiger BioPharmaceuticals' experimental drug for low blood sugar in a $35.1 million deal, Eiger said in a filing on ...